Organoids

Z Zhao, X Chen, AM Dowbaj, A Sljukic… - Nature Reviews …, 2022 - nature.com
Organoids are simple tissue-engineered cell-based in vitro models that recapitulate many
aspects of the complex structure and function of the corresponding in vivo tissue. They can …

Clinical cancer genomic profiling

D Chakravarty, DB Solit - Nature Reviews Genetics, 2021 - nature.com
Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …

Mechanisms and therapeutic implications of hypermutation in gliomas

M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu… - Nature, 2020 - nature.com
A high tumour mutational burden (hypermutation) is observed in some gliomas,,,–; however,
the mechanisms by which hypermutation develops and whether it predicts the response to …

[PDF][PDF] Oncogenic signaling pathways in the cancer genome atlas

F Sanchez-Vega, M Mina, J Armenia, WK Chatila… - Cell, 2018 - cell.com
Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …

Genetic and transcriptional evolution alters cancer cell line drug response

U Ben-David, B Siranosian, G Ha, H Tang, Y Oren… - Nature, 2018 - nature.com
Human cancer cell lines are the workhorse of cancer research. Although cell lines are
known to evolve in culture, the extent of the resultant genetic and transcriptional …

[PDF][PDF] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha… - Cancer Cell, 2022 - cell.com
The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …

Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - jamanetwork.com
Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …

Cas9 activates the p53 pathway and selects for p53-inactivating mutations

OM Enache, V Rendo, M Abdusamad, D Lam… - Nature …, 2020 - nature.com
Cas9 is commonly introduced into cell lines to enable CRISPR–Cas9-mediated genome
editing. Here, we studied the genetic and transcriptional consequences of Cas9 expression …

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

A Zehir, R Benayed, RH Shah, A Syed, S Middha… - Nature medicine, 2017 - nature.com
Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

The emerging clinical relevance of genomics in cancer medicine

MF Berger, ER Mardis - Nature reviews Clinical oncology, 2018 - nature.com
The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …